References
- KeithSJKaneJMPartial compliance and patient consequences in schizophrenia: our patients can do betterJ Clin Psychiatry200364111308131514658944
- KaneJMLeuchtSCarpenterDThe expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summaryJ Clin Psychiatry200364Suppl 12S5S19
- NasrallahHAThe case for long-acting antipsychotic agents in the post-CATIE eraActa Psychiatr Scand2007115426026717355516
- KaneJMStrategies for improving compliance in treatment of schizophrenia by using a long-acting formulation of an antipsychotic: clinical studiesJ Clin Psychiatry200364Suppl 16S34S40
- LaurielloJLambertTAndersenSAn 8-week, double-blind, randomized, placebo-controlled study of olanzapine long-acting injection in acutely ill patients with schizophreniaJ Clin Psychiatry200869579079918452346
- MamoDKapurSKeshavanMD2 receptor occupancy of olanzapine pamoate depot using positron emission tomography: an open-label study in patients with schizophreniaNeuropsychopharmacology200833229830417443131
- DetkeHMcDonnellDKaneJOlanzapine long-acting injection for the maintenance treatment of schizophrenia: a 24-week, randomized, double-blind trialSchizophr Res2008102Suppl 2262263
- Ascher-SvanumHMontgmeryWBrnabicATreatment completion rates of olanzapine and risperidone in long acting injectable formulations for the treatment of schizophrenia: a comparison of single arm open-label studiesSchizophr Res2008Suppl 2278
- Eli Lilly and Company; Pharmacokinetic Characterization of Intramuscular Olanzapine Depot (Clinical Trails ID: NCT00094640; F1D-EW-LOBS). http://clinicaltrials.gov/ct2/show/NCT00094640?term=NCT00094640&rank=1
- Eli Lilly and Company; Comparison of Intramuscular Olanzapine Depot With Placebo in the Treatment of Patients With Schizophrenia (Clinical Trails ID: NCT00088478, F1D-MC-HGJZ). http://clinicaltrials.gov/ct2/show/NCT00088478?term=NCT00088478&rank=1
- Eli Lilly and Company; Open-Label Study of Intramuscular Olanzapine Depot in Patients With Schizophrenia or Schizoaffective Disorder (Clinical Trails ID: NCT00088465). http://clinicaltrials.gov/ct2/show/NCT00088465?term=NCT00088465&rank=1
- Eli Lilly and Company. Olanzapine Pamoate Depot Versus Oral Olanzapine on Treatment Outcomes in Outpatients With Schizophrenia. ClinicalTrials ID: NCT00320489. http://clinicaltrials.gov/ct2/show/NCT00320489?term=NCT00320489&rank=1
- KuntzHBergstroomRMsDonnellDPharmocokinetics (PK) of multiple doses of olanzapine long acting injection (OLAI), an intramuscular (IM) depot formulation of olanzapine (OLZ), in stabilized patients with schizophreniaBiol Psychiatry200863288S
- DetkeHMcDonnellDKaneJEfficacy and safety of olanzapine long-acting injection for maintenance treatment of schizophreniaEur Neuropsychopharmacol200818Suppl 4S393S394
- McDonnellDLong-term open-label safety of olanzapine long-acting injection: 190-week interim resultsAmerican Psychiatric Association. 162nd Annual Meeting 2009:Abstract NRI-060:25.
- DetkeHZhaoFAndersenSComparison of olanzapine long-acting injection switching methods: an 8-month analysis of patients with schizophrenia of risk of relapseAmerican Psychiatric Association. 162nd Annual Meeting 2009:Abstract NRI-023:9.
- DetkeHMcDonnellDAndersenSOlanzapine long-acting injection in patients with schizophrenia at risk of relapse: 12-week switching dataEur Neuropsychopharmacol200818Suppl 14S435
- ZhaoFDetkeHCarlsonJAcute Efficacy of olanzapine long-acting injection, oral olanzapine, and haloperidol in patients with schizophrenia: cross-study comparisonAmerican Psychiatric Association. 162nd Annual Meeting 2009:Abstract NRI-099:40.
- GulliverADetkeHMcDonnellDPOlanzapine Long acting injection: Pharamcokinetics and dose correspondence data relative to oral olanzapineInt J Neuropsychopharamcol200811Suppl 1152153
- McDonnelDSorsaburuSBrunnerEDetkeHPostinjection delirium/sedation syndrome observed with olanzapine long acting injection: Review of the first 25 eventsEur Neuropsychopharmacol200818Suppl 4S437S438
- TaylorDPsychopharmacology and adverse effects of antipsychotic long-acting injections: a reviewBr J Psychiatry2009195S13S19
- UchidaHMamoDCKapurSLabelleAShammiCMannaertEJLMonthly administration of long-acting injectable risperidone and striatal dopamine D2 receptor occupancy for the management of schizophreniaJ Clin Psychiatry20086981281128618642974